The U.S. Census Bureau and the Department of Housing and Urban Development reported Wednesday morning that new housing starts in March rose to a seasonally adjusted annual rate of 946,000. That was an increase of 2.8% from the upwardly revised February rate of 920,000 and a drop of 5.9% compared with the March 2013 rate of 1 million. The consensus estimate from a survey of economists expected a rate of around 965,000.
The seasonally adjusted rate of new building permits fell to 990,000, which is 2.4% below the downwardly revised February rate of 1.01 million but 11.2% higher than the March 2013 rate of 890,000. The consensus estimate called for 1.01 million new permits.
Single-family housing starts rose to an annualized rate of 635,000 in March, up 6% from the revised February rate of 599,000.
Permits for new single-family homes rose 0.5% in March, to an adjusted annual rate of 592,000, from an upwardly revised total of 589,000 in February.
The number of housing starts for February was revised upward, from an original estimate of 909,000 to 920,000. That makes the March showing look even better. Multifamily starts for buildings with two to four units, a more volatile number than single-family starts, decreased 8% in March. The multifamily starts for units of five or more was up 39.1% compared with March 2013.
NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.
But if you missed out on NVIDIA’s historic run, your chance to see life-changing profits from AI isn’t over.
The 24/7 Wall Street Analyst who first called NVIDIA’s AI-fueled rise in 2009 just published a brand-new research report named “The Next NVIDIA.”
The report outlines key breakthroughs in AI and the stocks ready to dominate the next wave of growth. The report is absolutely free. Simply enter your email below
By providing your email address, you agree to receive communications from us regarding website updates and other offerings that may be of interest to you.
You have the option to opt-out of these emails at any moment. For more information, please review our Disclaimer and Terms of Use.